Español English Contacte con nosotros http://www.uc3m.es/portal/page/portal/biblioteca
DSpace e-Archivo

Archivo Abierto Institucional de la Universidad Carlos III de Madrid > Investigación > Departamentos > Departamento de Bioingeniería e Ingeniería Aeroespacial: Bioingeniería > DBIAB - Journal Articles >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10016/14598

Files in This Item:
experiment_NMB_2004_ps.pdf288,27 kBAdobe PDFformato pdf
Title: Experiment assessment of mass effects in the rat_ implications for small animal PET imaging
Author(s): Jagoda, E. M.
Vaquero, Juan José
Seidel, Jürgen
Green, Michael V.
Eckelman, William C.
Publisher: Elsevier
Issued date: Aug-2004
Citation: Nuclear Medicine and Biology, vol. 31, n. 6, aug. 2004. Pp. 771-779
URI: http://hdl.handle.net/10016/14598
ISSN: 0969-8051
DOI: 10.1016/j.nucmedbio.2004.04.003
Abstract: In vivo imaging using positron emission tomography (PET) is important in the development of new radiopharmaceuticals in rodent animal models for use as biochemical probes, diagnostic agents, or in drug development. We have shown mathematically that, if small animal imaging studies in rodents are to have the same “quality” as human PET studies, the same number of coincidence events must be detected from a typical rodent imaging “voxel” as from the human imaging voxel. To achieve this using the same specifi activity preparation, we show that roughly the same total amount of radiopharmaceutical must be given to a rodent as to a human subject. At high specifi activities, the mass associated with human doses, when administered to a rodent, may not decrease the uptake of radioactivity at non saturable sites or sites where an enzyme has a high capacity for a substrate. However, in the case of binding sites of low density such as receptors, the increased mass injected could saturate the receptor and lead to physiologic effects and non-linear kinetics. Because of the importance of the mass injected for small animal PET imaging, we experimentally compared high and low mass preparations using ex vivo biodistribution and phosphorimaging of three compounds: 2-fluoro-2-deoxyglucos (FDG), 6-fluoro-L-metatyrosin (FMT) and one receptor-directed compound, the serotonin 5HT1A receptor ligand, trans-4-fluoro-N-{2-[4-(2-methoxylphenyl piperazino]ethyl}-N-(2- pyridyl) cyclohexane- carboxamide (FCWAY). Changes in the mass injected per rat did not affect the distribution of FDG, FMT, and FCWAY in the range of 0.6 –1.9 nmol per rat. Changes in the target to nontarget ratio were observed for injected masses of FCWAY in the range of 5–50 nmol per rat. If the specifi activity of such compounds and/or the sensitivity of small animal scanners are not increased relative to human studies, small animal PET imaging will not correctly portray the “true” tracer distribution. These difficultie will only be exacerbated in animals smaller than the rat, e.g., mice.
Publisher version: http://dx.doi.org/10.1016/j.nucmedbio.2004.04.003
Keywords: Animal imaging
PET
FDG
FMT
FCWAY
Rights: © Elsevier
Appears in Collections:DBIAB - Journal Articles

Refworks Export

SFX Query

Items in E-Archivo are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! © Universidad Carlos III de Madrid - Software DSpace - Terms of use - Feedback